Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kintsugi’s AI Software Analyzes Voice For Signs Of Depression, Anxiety

Executive Summary

Kintsugi is developing an AI-driven software that analyzes voice to detect depression and anxiety, offering clinicians an early screening tool in call centers, telehealth and remote monitoring.

You may also be interested in...



Digital Health Roundup: Voice Biomarkers; SXSW, LSI, ACC; FTC BetterHelp Settlement

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb discusses conference highlights from SXSW and LSI while Barnaby Pickering talks about his coverage on voice biomarkers. Hannah Daniel discusses BetterHelp’s return of $7.8m to customers to settle with FTC for sharing health data.

CES 2022: Defying Omicron, World’s Biggest Tech Show Goes Live In Las Vegas

CES 2022 is missing some marquee names due to the coronavirus surge, but there’s still plenty to take in at the intersection of digital health and consumer tech. In this roundup, Medtech Insight highlights some standouts, with commentary from company leaders.

Canary Speech’s Voice AI Can Help Detect Alzheimer’s With 40-Second Conversation

AI voice tech start-up Canary Speech is developing algorithmic models for detecting behavioral health, progressive neurological and cognitive diseases based on a 40-second recording of speech. Medtech Insight caught up with Canary CEO Henry O’Connell at DHIS West to learn more about the company and its plans.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel